Funded Startups in Strasbourg
Recent disclosed rounds in Strasbourg span from HypnoVR’s Series A on 2021-12-07 ($5M) to Sounduct’s Seed on 2025-06-03 ($3M).
Recent disclosed rounds in Strasbourg span from HypnoVR’s Series A on 2021-12-07 ($5M) to Sounduct’s Seed on 2025-06-03 ($3M). The largest disclosed amount in the 11-row slice is SUPERBRANCHE’s $13M (2025-02-04), which stands out above the rest; the next-largest disclosed amounts are $6M (Aerleum, 2024-10-14) and then $5M (Dianosic, 2023-02-06; HypnoVR, 2021-12-07). Two “concentration” patterns show up: four entries fall between 2024-07-11 and 2025-03-13 (Scalingo $4M on 2024-07-11; Aerleum $6M on 2024-10-14; BiPER Therapeutics $840K on 2024-12-17; Fizimed $4M on 2025-03-13), and health care-related companies appear repeatedly (Fizimed, BiPER Therapeutics, Kwit, SPARTHA Medical, plus health-adjacent coverage for SUPERBRANCHE). Stage classification is also uneven: only two rows are Seed (Sounduct 2025-06-03 $3M; Aerleum 2024-10-14 $6M; Dianosic 2023-02-06 $5M; SPARTHA Medical 2022-01-25 $3M) while Series A appears twice (Scalingo $4M in 2024-07-11 and HypnoVR $5M in 2021-12-07), and five entries are labeled Series Unknown.
Most recent rounds
11 shownRelated listings
Frequently asked
What’s the largest disclosed round shown for Strasbourg, and how far ahead is it of the next-largest?
The largest disclosed amount is SUPERBRANCHE’s $13M on 2025-02-04. That figure is clearly above the next-largest disclosed amounts: Aerleum’s $6M (2024-10-14) and then the $5M group (Dianosic on 2023-02-06 and HypnoVR on 2021-12-07).
Do the most recent rounds cluster into a narrow window?
Yes. Four rounds land between 2024-12-17 and 2025-06-03: BiPER Therapeutics $840K (2024-12-17), SUPERBRANCHE $13M (2025-02-04), Fizimed $4M (2025-03-13), and Sounduct $3M (2025-06-03).
Is health care over-represented versus other sectors in this Strasbourg list?
Health care appears in 4 of the 11 rows with explicit sector labels: Fizimed (2025-03-13, $4M), Kwit (2025-01-17, $360K), BiPER Therapeutics (2024-12-17, $840K), and SPARTHA Medical (2022-01-25, $3M). Biotechnology adds additional coverage via SUPERBRANCHE and Dianosic (both labeled Biotechnology).
How dominant is “Series Unknown” or “undisclosed” in the disclosed-stage picture?
Stage labels are incomplete for much of the slice: five entries are marked Series Unknown (Fizimed, SUPERBRANCHE, Kwit, BiPER Therapeutics, Cephalgo), and one amount is explicitly undisclosed for Cephalgo (2023-06-23). Seed and Series A together account for the remaining visible classifications (including Seed: Sounduct, Aerleum, Dianosic, SPARTHA Medical; Series A: Scalingo and HypnoVR).
Are there outliers that change how the funding distribution looks?
Two stand out on amounts: Kwit’s $360K (2025-01-17) is the smallest disclosed amount shown, while SUPERBRANCHE’s $13M (2025-02-04) is the only disclosed round above $10M. Cephalgo’s $ undisclosed amount (2023-06-23) is another outlier in terms of missing disclosed funding size.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.